Zobrazeno 1 - 10
of 206
pro vyhledávání: '"Sijts, Alice"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Lyu, Qingkang, Ludwig, Irene S., Kooten, Peter J. S., Sijts, Alice J. A. M., Rutten, Victor P. M. G., van Eden, Willem, Broere, Femke
Publikováno v:
Cell Stress & Chaperones, 2020 Mar 01. 25(2), 235-243.
Externí odkaz:
https://www.jstor.org/stable/48724445
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
In Vaccine 15 December 2017 35(50):7057-7063
Autor:
de Groot, Anne Marit, Du, Guangsheng, Mönkäre, Juha, Platteel, Anouk C.M., Broere, Femke, Bouwstra, Joke A., Sijts, Alice J.A.M.
Publikováno v:
In Journal of Controlled Release 28 November 2017 266:27-35
Autor:
Huynh, Dung T., Nolfi, Emanuele, Medfai, Lobna, van Ulsen, Peter, Jong, Wouter S. P., Sijts, Alice J. A. M., Luirink, Joen
Publikováno v:
Human Vaccines & Immunotherapeutics; 2024, Vol. 20 Issue 1, p1-12, 12p
Autor:
Platteel, Anouk C.M., Marit de Groot, A., Keller, Christin, Andersen, Peter, Ovaa, Huib, Kloetzel, Peter M., Mishto, Michele, Sijts, Alice J.A.M.
Publikováno v:
In Vaccine 30 September 2016 34(42):5132-5140
Autor:
Vukovic, Natasa, Segues Cistero, Aina, Huang, Shuyu, Waterfall, Martin, Sijts, Alice, Zaiss, Dietmar
Publikováno v:
Vukovic, N, Segues Cistero, A, Huang, S, Waterfall, M, Sijts, A & Zaiss, D 2023, ' In a therapeutic setting, mouse IgG2a isotype is superior to mIgG1 or mIgE in controlling tumor growth ', Cancer research communications . https://doi.org/10.1158/2767-9764.CRC-22-0356
In the last decades, antibody based tumor therapy has fundamentally improved the efficacy of treatment for cancer patients. Currently, almost all tumor-antigen targeting antibodies approved for clinical application are of IgG1 Fc-isotype. Similarly,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3094::36c5716e07d48689c2ff60e8ccf6e007
https://www.pure.ed.ac.uk/ws/files/321152375/crc_22_0356.pdf
https://www.pure.ed.ac.uk/ws/files/321152375/crc_22_0356.pdf
Autor:
Vukovic, Natasa, Segués, Aina, Huang, Shuyu, Waterfall, Martin, Sijts, Alice J A M, Zaiss, Dietmar M, Immunologie
Publikováno v:
Cancer research communications, 3(1), 109
Cancer Res Commun
Cancer Res Commun
In the last decades, antibody-based tumor therapy has fundamentally improved the efficacy of treatment for patients with cancer. Currently, almost all tumor antigen–targeting antibodies approved for clinical application are of IgG1 Fc isotype. Simi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8776ca999985d991073d854ea380e68f
https://dspace.library.uu.nl/handle/1874/427694
https://dspace.library.uu.nl/handle/1874/427694
Autor:
Huang, Shuyu, Segués, Aina, Waterfall, Martin, Wright, David, Vayssiere, Charlotte, van Duijnhoven, Sander M J, van Elsas, Andrea, Sijts, Alice J A M, Zaiss, Dietmar M, Infectious Diseases and Immunology, Immunologie
Publikováno v:
Biomolecules; Volume 12; Issue 10; Pages: 1331
Biomolecules, 12(10), 1. Multidisciplinary Digital Publishing Institute (MDPI)
Huang, S, Segués, A, Waterfall, M, Wright, D, Vayssiere, C, Van Duijnhoven, S M J, Van Elsas, A, Sijts, A J A M & Zaiss, D M 2022, ' Shortened hinge design of Fab x sdAb-Fc bispecific antibodies enhances redirected T-Cell killing of tumor cells ', Biomolecules, vol. 12, no. 10, 1331 . https://doi.org/10.3390/biom12101331
Biomolecules, 12(10), 1. Multidisciplinary Digital Publishing Institute (MDPI)
Huang, S, Segués, A, Waterfall, M, Wright, D, Vayssiere, C, Van Duijnhoven, S M J, Van Elsas, A, Sijts, A J A M & Zaiss, D M 2022, ' Shortened hinge design of Fab x sdAb-Fc bispecific antibodies enhances redirected T-Cell killing of tumor cells ', Biomolecules, vol. 12, no. 10, 1331 . https://doi.org/10.3390/biom12101331
T cell engager (TCE) antibodies have emerged as promising cancer therapeutics that link cytotoxic T-cells to tumor cells by simultaneously binding to CD3E on T-cells and to a tumor-associated antigen (TAA) expressed by tumor cells. We previously repo